Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.

You may also be interested in...



Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation

FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.

FDA’s Prasugrel Presentation To Advisory Committee Eases Doubts On Approvability

FDA presentation put the advisory committee at ease with prasugrel’s benefit-risk profile and may have turned the tide toward approvability.

Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation

FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel